Versant Capital Management, Inc Bridge Bio Pharma, Inc. Transaction History
Versant Capital Management, Inc
- $454 Million
- Q4 2024
A detailed history of Versant Capital Management, Inc transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 38 shares of BBIO stock, worth $1,105. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38
Previous 38
-0.0%
Holding current value
$1,105
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BBIO
# of Institutions
290Shares Held
170MCall Options Held
10.4MPut Options Held
2.37M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$735 Million35.94% of portfolio
-
Viking Global Investors LP25.1MShares$731 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$413 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$362 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$176 Million63.58% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $4.31B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...